drugset / Trial / NCT04426851

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

NCT04426851

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of Part 1 of this trial is to investigate the absolute bioavailability of BI 1358894 with an intravenous microdose formulation containing labelled \[C-14\] BI 1358894 and an unlabelled oral tablet formulation of BI 1358894 in healthy male subjects. The main objective of Part 2 of this trial is to investigate the relative bioavailability of BI 1358894 administered as an oral suspension.

Timeline

Start
2020-07-13
Primary completion
2020-10-12
Completion
2020-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule Oral

Indications

No indication recorded.